Evolent Health, Inc. (EVH)

Evolent Health beat on both lines in the fiscal second quarter of 2026, reported on August 6, as adjusted EPS of $0.02 topped the -$0.01 estimate by about 292% and revenue of about $652.5 million exceeded the $597.7 million consensus by roughly 9%. Revenue rose about 47% from $444.3 million a year ago, while gross profit came to about $80.8 million and gross margin was 12.4%; operating income was negative $9.6 million, with operating margin at -1.5%. Net income was negative $28.4 million, down about 43% from negative $19.9 million a year earlier, and operating cash flow was negative $10.3 million. Consensus for the next period calls for adjusted EPS of $0.07 on revenue of $685.0 million.